TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance
Nathalie Wong(Chinese University of Hong Kong), Ka‐Fai To(Chinese University of Hong Kong), Jane Koh(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), Joanna H. Tong(Chinese University of Hong Kong), Philip J. Johnson(Prince of Wales Hospital), Stephen L. Chan(Chinese University of Hong Kong), Frankie Mo(Chinese University of Hong Kong), Kathy Yuen Yee Chan(Chinese University of Hong Kong), Ho‐Keung Ng(Chinese University of Hong Kong), Arthur K. Ching(Chinese University of Hong Kong), Anthony T.�C. Chan(Chinese University of Hong Kong), Wai‐Lap Wong(Chinese University of Hong Kong), Navy L. Y. Wong(Chinese University of Hong Kong), Winnie Yeo(Chinese University of Hong Kong)
Cited by 196
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k